PH027-1, a potent WRN inhibitor with a wide safety margin and efficacy against MSI-H tumors

April 10, 2024

Researchers from Puhe Biopharma Co. Ltd. presented the discovery and preclinical evaluation of PH027-1, a novel small-molecule Werner syndrome protein (WRN) inhibitor targeting microsatellite instability high (MSI-H) tumors.

BioWorld Science Conferences New compound American Association for Cancer Research Cancer

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 24, 2025.

Regulatory actions for April 24, 2025

BioWorld

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cel-Sci, Novavax,...

Go ask Alis? New fund aims to rescue biopharma’s trapped cash

BioWorld

“They are not zombies, they are fallen angels.” That is view of Nick Johnston, a U.K-based banker who has come up with a new plan to rescue listed companies whose...

Dan Chen, founder and CEO, Synthetic Design Lab

Synthetic Design emerges with $20M and next-gen ADC platform

BioWorld

Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC)...